Hunilife Biotechnology, Inc.

This early-stage study tested a new drug, HuL001, in 24 people to see if it is safe and how the body processes it. The trial included both healthy volunteers and patients with idiopathic pulmonary fibrosis, a serious lung disease that causes scarring. Researchers monitored side e…